David B. Thomson serves as the Executive Vice President, General Counsel, and Secretary at MannKind Corporation, a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. In his role, Thomson is responsible for overseeing the company's legal affairs, ensuring compliance with regulatory requirements, and providing strategic guidance to the executive team. His leadership has been instrumental in navigating the complex legal landscape of the pharmaceutical industry, helping MannKind Corporation achieve its mission of improving the lives of patients worldwide. Prior to joining MannKind Corporation, Thomson held several high-profile positions in the legal field. He began his career at a prestigious law firm, where he specialized in corporate law and intellectual property. His expertise in these areas allowed him to successfully represent clients in various industries, including pharmaceuticals, biotechnology, and technology. Thomson's impressive track record and deep understanding of the legal challenges facing the life sciences sector made him a valuable asset to MannKind Corporation when he joined the company in 2017. Since then, he has played a key role in the company's growth and success, including the successful launch of several innovative products and the expansion of MannKind's global presence. Throughout his career, Thomson has been recognized for his outstanding contributions to the legal profession and the life sciences industry. He is a frequent speaker at industry conferences and has published numerous articles on topics related to corporate law, intellectual property, and regulatory compliance. Thomson's dedication to excellence, combined with his strategic vision and leadership skills, have made him an invaluable member of the MannKind Corporation team. As the company continues to grow and innovate, Thomson's role as EVP, General Counsel, and Secretary will remain crucial in ensuring that MannKind Corporation maintains its position as a leader in the development of life-changing therapies.